Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials

Documents similaires

• Why do patients with obesity discontinue glucagon‐like peptide 1 analogues?
  par: Faisal I. Almohaileb, et autres
  Publié: (2025)
• Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
  par: Giovanni Antonio Silverii, et autres
  Publié: (2024)
• Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
  par: Dario Giugliano, et autres
  Publié: (2025)
• Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m 2 in the phase 2 trial of survodutide, a glucagon/ GLP ‐1 receptor dual agonist
  par: Carel W. le Roux, et autres
  Publié: (2025)
• Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial
  par: Carel W. le Roux, et autres
  Publié: (2024)